New York State Common Retirement Fund Has $1.08 Million Position in Global Blood Therapeutics, Inc. (GBT)

New York State Common Retirement Fund increased its position in Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 102.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 39,500 shares of the company’s stock after acquiring an additional 20,012 shares during the period. New York State Common Retirement Fund owned approximately 0.09% of Global Blood Therapeutics worth $1,080,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in GBT. BNP Paribas Arbitrage SA grew its position in Global Blood Therapeutics by 694.9% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,547 shares of the company’s stock valued at $124,000 after buying an additional 3,975 shares in the last quarter. Legal & General Group Plc grew its position in Global Blood Therapeutics by 10.1% in the 1st quarter. Legal & General Group Plc now owns 4,816 shares of the company’s stock valued at $178,000 after buying an additional 440 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new position in Global Blood Therapeutics in the 2nd quarter valued at about $211,000. SG Americas Securities LLC grew its position in Global Blood Therapeutics by 93.9% in the 2nd quarter. SG Americas Securities LLC now owns 8,288 shares of the company’s stock valued at $227,000 after buying an additional 4,014 shares in the last quarter. Finally, Bank of America Corp DE grew its position in Global Blood Therapeutics by 103.6% in the 1st quarter. Bank of America Corp DE now owns 7,141 shares of the company’s stock valued at $263,000 after buying an additional 3,633 shares in the last quarter. 86.22% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “New York State Common Retirement Fund Has $1.08 Million Position in Global Blood Therapeutics, Inc. (GBT)” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.com-unik.info/2017/11/03/new-york-state-common-retirement-fund-has-1-08-million-position-in-global-blood-therapeutics-inc-gbt.html.

A number of brokerages recently issued reports on GBT. Oppenheimer Holdings, Inc. set a $53.00 target price on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research report on Monday. BidaskClub lowered shares of Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 19th. J P Morgan Chase & Co reiterated a “buy” rating on shares of Global Blood Therapeutics in a research report on Monday, October 23rd. Zacks Investment Research upgraded shares of Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $36.00 target price for the company in a research report on Tuesday, October 10th. Finally, Needham & Company LLC began coverage on shares of Global Blood Therapeutics in a research report on Wednesday, September 20th. They issued a “buy” rating and a $51.00 target price for the company. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $54.08.

Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings data on Tuesday, November 7th. The company reported ($0.66) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.04). During the same period in the previous year, the business posted ($0.58) earnings per share.

In related news, insider Jung Choi sold 3,000 shares of Global Blood Therapeutics stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $30.00, for a total value of $90,000.00. Following the completion of the sale, the insider now directly owns 140,055 shares in the company, valued at $4,201,650. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Peter Radovich sold 12,500 shares of Global Blood Therapeutics stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $35.00, for a total value of $437,500.00. Following the completion of the sale, the vice president now owns 2,684 shares of the company’s stock, valued at $93,940. The disclosure for this sale can be found here. Over the last quarter, insiders sold 91,500 shares of company stock valued at $3,093,350. Corporate insiders own 5.30% of the company’s stock.

Global Blood Therapeutics Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics, Inc. (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

What are top analysts saying about Global Blood Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Global Blood Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit